Alexandria Venture Investments returned to invest in a series C round that lifted the radiopharmaceutical developer's overall funding to $258m.
Alexandria Venture Investments, the venture capital subsidiary of life sciences real estate investment trust Alexandria Real Estate Equities, took part in a $108m series C round for US-based radiopharmaceutical developer RayzeBio yesterday.
The round was led by Venrock Healthcare Capital Partners, a fund managed by venture capital firm Venrock, and included new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management and TCG Crossover.
The round also featured existing backers VenBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking…
